The CD40 ligand: At the center of the immune universe?

Immunologic Research

Volumn 16, Issue 1, 1997, Pages 59-70

  Grewal, Iqbal S ^a   Flavell, Richard A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; CD40L T cell activation; Parasitic infections; T cell effector functions; T cell priming

Indexed keywords

GLYCOPROTEIN GP 39;

B LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; ENDOTHELIUM CELL; FIBROBLAST; HUMORAL IMMUNITY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0030996214     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786323     Document Type: Review

References (71)

1. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Ann Rev Immunol 1994; 12: 881-922.
2. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al.: Molecular and biological characterization of a murine ligand for CD40. Nature 1992;357:80-82.
3. Cocks BG, de Waal Malefyt R, Galizzi JP, de Vries JE, Aversa G: IL-13 induces proliferation and differentiation of human B-cells activated by the CD40 ligand. Intl Immunol 1993;5:657-663.
4. Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J, Kishi K, Butterfield J, Dahinden C, Bonnefoy JY: Induction of human IgE synthesis in B-cells by mast cells and basophils. Nature 1993;365:340-343.
5. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L: Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med 1992;175:1091-1101.
6. Noelle RJ, Ledbetter JA, Aruffo A: CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992;13:431-433.
7. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, Maliszewski CR, Fanslow WC: Recombinant human CD40 ligand stimulates B-cell proliferation and immunoglobulin E secretion. J Exp Med 1992;176: 1543-1550.
8. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A: The human T-cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B-cell co-stimulatory activity. EMBO J 1992;11: 4313-4321.
9. Graf D, Korthauer U, Mages HW, Senger G, Kroczek RA: Cloning of TRAP, a ligand for CD40 on human T-cells. Eur J Immunol 1992;22:3191-3194.
10. Grewal IS, Flavell RA: CD40-CD40L interactions in T-cell activation. Immunol Rev 1996;153: in press.
11. Callard RE, Armitage RJ, Fanslow WC, Spriggs MK: CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today 1993; 14:559-564.
12. Foy TM, Aruffo A, Ledbetter JA, Noelle RJ: In vivo CD40-gp39 interactions are essential for thymus-dependent immunity. II. Prolonged in vivo suppression of primary and secondary humoral immune responses by an antibody targeted to the CD40 ligand, gp39. J Exp Med 1993;178:1567-1575.
13. Ramesh N, Fuleihan R, Geha, R: Molecular pathology of X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Immunol Rev 1994;138:87-104.
14. Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA: Mice deficient for the CD40 ligand. Immunity 1994;1:423-431.
15. Renshaw BR, Fanslow WC, Armitage RJ, Cambell KA, Liggit D, Wright B, et al.: Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 1994;180: 1889-1900.
16. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H: The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1:167-178.
17. Grewal IS, Xu J, Flavell RA: Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995;378: 617-620.
18. Grewal IS, Flavell RA A central role of CD40 ligand in the regulation of CD4 T-cell responses. Immunol Today 1996;17:410-414.
19. Grewal IS, Flavell RA: Role of CD40 ligand in immunity and autoimmunity; in Plotkin S, Fantini B (eds.) Immune Tolerance. Elsevier, Paris: 1996, in press.
20. Noelle RJ: CD40 and its ligand in host defense. Immunity 1996;4: 415-419.
21. Yellin MJ, Brett J, Baum D, Matsushima A, Szabolcs M, Stern D, Chess L: Functional interactions of T-cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med 1995; 182:1857-1864.
22. Eynon EE, Parker DC: Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 1992;175:131-138.
23. Fuchs EJ, Matzinger P: B cells turn off virgin but not memory T cells. Science 1992;258:1156-1159
24. Linsley PS, Ledbetter JA.: The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993;11:191-212
25. Janeway CA Jr, Bottomly K: Signals and signs for lymphocyte responses. Cell 1994;76:275-285
26. Jenkins MK: The ups and downs of T cell costimulation. Immunity 1994;1:443-446
27. Ranhei, EA, Kipps TJ: Activated T cells induce expression of B7/ BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925-935.
28. Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R: Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol 1995; 25:596-603.
29. Kearne, RR, Pape KA, Loh DY, Jenkins MK: Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994;94:327-339.
30. Wu Y, Xu J, Shinde S, Grewal, IS, Henderson T, Flavell RA, Liu Y: Rapid induction of a novel costimulatory activity on B cells by CD40 ligand. Curr Biol 1995;5:1303-1311.
31. Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA., Green, WR, Xu J, Shultz LD, Roopesian D, Flavell RA, Loran F, Noelle RJ, Durie FH: In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995;2:645-653.
32. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-1808.
33. Bolling SF, Lin H, Wei RQ, Linsley P, Turka LA: The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival. J Surg Res 1994;57:60-64.
34. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J: Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180:1263-1272.
35. Peguet-Navarro J, Dalbiez-Gauthier C, Rattis FM, Van Kooten C, Banchereau J. Schmitt D: Functional expression of CD40 antigen on human epidermal Langerhans cells. J Immunol 1995;155:4241-4247.
36. Cella M, Scheidegger D, Palmer-Lehman K, Lane P, Lanzavecchia A, Alber G: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184;747-752.
37. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G: High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-10. J Exp Med 1996;184:741-746.
38. Aversa G, Punnonen J, de Vries JE: The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides acostimulatory signal for human B cell activation. J Exp Med 1993;177:1575-1585.
39. Macchia D, Almerigogna F, Parronchi P, Ravina A, Maggi E, Romagnani S: Membrane tumour necrosis factor-alpha is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 1993;63:464-466.
40. Rodriguez C, Roldan E, Navas G, Brieva JA: Essential role of tumor necrosis factor-alpha in the differentiation of human tonsil in vivo induced B cells capable of spontaneous and high-rate immunoglobulin secretion. Eur J Immunol 1993;23:1160-1164.
41. Larrick JW, Wright SC: Cytotoxic mechanism of tumor necrosis factor-alpha. FASEB J 1990;4: 3215-3223.
42. Hernandez-Caselles T, Stutman O: Immune functions of tumor necrosis factor. I. Tumor necrosis factor induces apoptosis of mouse thymocytes and can also stimulate or inhibit IL-6-induced proliferation depending on the concentration of mitogenic costimulation. J Immunol 1993;151:3999-4012.
43. Notarangelo LD, Duse M, Ugazio AG: Immunodeficiency with hyperIgM (HIM). Immunodefic Rev 1992;3:101-122.
44. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ: Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261:1328-1330.
45. Mohan C, Shi Y, Laman JD, Datta SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470-1480.
46. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996;93:2499-2504.
47. Griggs ND, Agersborg SS, Noelle RJ, Ledbetter JA, Linsley PS, Tung KS: The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J Exp Med 1996;183:801-810.
48. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS: CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995;92:4342-4346.
49. Lehmann PV, Forsthuber T, Miller A, Sercarz EE: Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-157.
50. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD: Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182:75-85.
51. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA Jr, Flavell RA: Requirement for CD40 ligand in costimulation induction, T cell activation and experimental allergic encephalomyelitis. Science 1996;273:1864-1867.
52. Stout R, Suttles J: The many roles of CD40: CD40L interactions in cell-mediated inflammatory responses. Immunol Today 1996;17:487-492.
53. Stout R, Suttles J, Xu J, Grewal I, Flavell R: Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 1996;156:8-11.
54. Wagner DH Jr, Stout RD, Suttles J: Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol 1994;24:3148-3154.
55. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D: Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917-4925.
56. Tao X, Stout RD: T-cell-mediated cognate signaling of nitric oxide production by macrophages. Requirements for macrophage activation by plasma membranes isolated from T cells. Eur J Immunol 1993;23:2916-2921.
57. Tian L, Noelle RJ, Lawrence DA: Activated T-cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol 1995;25: 306-309.
58. Stout RD: Macrophage activation by T cells: cognate and non-cognate signals. CurrOpinion Immunol 1993;5:398-403.
59. Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately M, Delespesse G: Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 1995;25:1125-1128.
60. Afonso LC, Scott P: Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993;61:2952-2959.
61. Reiner SL, Locksley RM: The regulation of immunity to Leishmania major. Ann Rev Immunol 1995:13:151-177.
62. Soong L, Xu J, Grewal IS, Kima P, Sun J, Longley Jr BJ, Ruddle NH, McMohan-Pratt D, Flavell RA: Disruption of CD40-CD40 ligand interactions results is an enhanced susceptibility to Leishmania amazonensis infection. Immunity 1996; 4:263-273.
63. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed, SG, Maliszewski, CR: CD40 Ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996;4:283-289.
64. Kamanaka M, Yu P, Yasui T, Yoshida K, Kawabe T, Horii T, Kishimoto T, Kikutani H: Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 1996;4:275-281.
65. Borrow P, Tishon A, Lee S, Xu J, Grewal IS, Oldstone MB, Flavell RA: CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J Exp Med 1996; 183:2129-2142.
66. Whitemire JK, Slifka MK, Grewal IS, Flavell RA, Ahmed R: CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection. J Virol 1996;70:8375-8381.
67. Kasaian MT, Leite-Morris KA, Biron CA: The role of CD4+ cells in sustaining lymphocyte proliferation during lymphocytic choriomeningitis virus infection. J Immunol 1991;146:1955-1963.
68. Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM: Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 1994;68:4700-4704.
69. von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL: CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol 1996;70: 1072-1079.
70. Ding L, Green JM, Thompson CB, Shevach EM: B7/CD28-dependent and independent induction of CD40 ligand expression. J Immunol 1995;155:5124-5132.
71. Jaiswal AI, Dubey C, Swain SL, Croft M. Regulation of CD40 ligand expression on naive CD T cells: a role for TCR but not co-stimulatory signals. Intl. Immunol 1996; 8:275-285.